Joseph Geraci

A mathematical physicist unravelling our circuitry...

[Joseph Geraci @NetraMark]

@citrini @AnthropicAI Look me up! @NetraMark_AI I’ve spent since 2016 on the patient population problem. Happy to discuss.

[Joseph Geraci @NetraMark]

@GenerationIron Great job Nick!

[Joseph Geraci @NetraMark]

@hurrdeep I totally get it. This match is so frustrating.

[Joseph Geraci @NetraMark]

@Road_Guy_Colin Just a garbage referee.

[Joseph Geraci @NetraMark]

I'm claiming my AI agent "topolift_karuna3" on @moltbook 🦞

Verification: seabed-SK6Y

[Joseph Geraci @NetraMark]

I'm claiming my AI agent "topolift_karuna2" on @moltbook 🦞

Verification: pincer-H9YF

[Joseph Geraci @NetraMark]

I'm claiming my AI agent "topolift_karuna2" on @moltbook

Verification: pincer-H9YF

[Joseph Geraci @NetraMark]

@MetabolicUncle @rohanpaul_ai Look up some of my work, if interested.

[Joseph Geraci @NetraMark]

@BakkenShale @DC_Draino If you see this pic and want to understand another side of how this terrible tragedy was used to weaponize against a drug that helps thousands of children yearly then read this:

https://t.co/p5t3ZdW26H

[Joseph Geraci @NetraMark]

@karlmehta This has made the biggest difference @NetraMark and inspires my newest work. Great post.

[Joseph Geraci @NetraMark]

@bindureddy Brilliantly true!

[Merlin_Asset @Merlin_Asset]

NetraMark $AIAI just dropped a 🔥 new investor deck!  

💰 Projected $8M-$10M contract backlog in the next 12 months.  

Rare AI stock with strong revenue & growth profile at just $150M market cap.  
Check it out: https://t.co/k3A132QP8U
#HealthcareAI #AIStocks $XBI

[NetraMark.AI @NetraMark_AI]

Ecstatic to announce an agreement with @worldwidetrials to transform how #globaltrials are designed & executed, leveraging our #AItechnology. We aim to speed development timelines by enabling more informed protocol development, faster decision-making, & improved patient targeting

[Merlin_Asset @Merlin_Asset]

“You know, right now, so much of clinical trials is a roll of the dice, and the failure rates are astronomical. What if AI could help us derisk that? What if we could use #AI to say, “Hey, this is the patient population that’s most likely to respond,” or “This is the trial design that’s most likely to succeed”? I think that’s a huge opportunity that’s still untapped.” - @vijaypande @a16z

Whats NetraMark $AIAI worth if it solves these questions? Markets telling us something.

[Joseph Geraci @NetraMark]

@HydroOne Now you estimate that we are getting our power back by Wed night?? No visibility from your side. You have inspired me to get serious about alternative means of powering our homes because clearly the infrastructure we are dealing with is very vulnerable.

[Joseph Geraci @NetraMark]

@fordnation No updates over the weekend. We needed to make decisions. Now they are saying we are out until Wednesday night in Durham! The lack of visibility is insane!

[U of T Arts & Science @UofTArtSci]

Joseph Geraci, a @VicCollege_UofT alum, is transforming the future of AI-powered drug discovery as founder and chief scientific officer of @NetraMark.

“The foundation of entrepreneurship is creativity,” says Geraci.

Read the latest A&S LinkedIn article: https://t.co/iTC9Wqm8wP

[Joseph Geraci @NetraMark]

I just wanted to share a piece about me and my work that came today out on the University of Toronto #UofT news channel. The current AI environment is perfectly aligned with our approach to improving clinical trials success rates.
https://t.co/JaoLaOYcp6

[Joseph Geraci @NetraMark]

People calling and asking me about DeepSeek AI. Personally, I believe there are ways of shrinking foundational models and creating them at a fraction of the cost. Companies like NetraMark are creating complementary methods that fuse and improve these models so exciting times!

[Joseph Geraci @NetraMark]

@basbloem Bas, if you’re game, I would love to discuss how we deal with these kinds of issues with a specialized mathematically augmented technology. Please let me know and we can connect. There may be subpopulations that show improvement. And what I’m offering is far from typical.